Activity of antimalarial drugs in vitro and in a murine model of cutaneous leishmaniasis

Journal of Medical Microbiology

Volumn 62, Issue PART7, 2013, Pages 1001-1010

  Rocha, Vinícius Pinto Costa ^a   Nonato, Fabiana Regina ^a   Guimarães, Elisalva Teixeira ^a,b   de Freitas, Luiz Antônio Rodrigues ^a,c   Soares, Milena Botelho Pereira ^a,d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSIDADE DO ESTADO DA BAHIA   (Brazil)

^c FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^d HOSPITAL SÃO RAFAEL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ARTESUNATE; CHLOROQUINE; CRYSTAL VIOLET; HYDROXYCHLOROQUINE; MEFLOQUINE; PRIMAQUINE;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; ENDOCYTOSIS; FEMALE; GOLGI COMPLEX; GROWTH INHIBITION; HISTOPATHOLOGY; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEISHMANIA; MALE; MOUSE; MULTIVESICULAR BODY; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS;

ANIMALS; ANTIMALARIALS; FEMALE; INHIBITORY CONCENTRATION 50; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA;

EID: 84879150643     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.058115-0     Document Type: Article

References (41)

1. Ashburn, T. T. & Thor, K. B. (2004). Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3, 673-683.
2. Awasthi, A., Mathur, R. K. & Saha, B. (2004). Immune response to Leishmania infection. Indian J Med Res 119, 238-258.
3. Bermudez, L. E., Kolonoski, P., Wu, M., Aralar, P. A., Inderlied, C. B. & Young, L. S. (1999). Mefloquine is active in vitro and in vivo against Mycobacterium avium complex. Antimicrob Agents Chemother 43, 1870-1874.
4. Bézivin, C., Tomasi, S., Lohézic-Le Dévéhat, F. & Boustie, J. (2003). Cytotoxic activity of some lichen extracts on murine and human cancer cell lines. Phytomedicine 10, 499-503.
5. Borges, V. M., Vannier-Santos, M. A. & de Souza, W. (1998). Subverted transferrin trafficking in Leishmania-infected macrophages. Parasitol Res 84, 811-822.
6. Byrd, T. F. & Horwitz, M. A. (1991). Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens. J Clin Invest 88, 351-357.
7. Chaves, S. P., Torres-Santos, E. C., Marques, C., Figliuolo, V. R., Persechini, P. M., Coutinho-Silva, R. & Rossi-Bergmann, B. (2009). Modulation of P2X7 purinergic receptor in macrophages by Leishmania amazonensis and its role in parasite elimination. Microbes Infect 11, 842-849.
8. Croft, S. L., Sundar, S. & Fairlamb, A. H. (2006). Drug resistance in leishmaniasis. Clin Microbiol Rev 19, 111-126.
9. de Oliveira Cardoso, F., de Souza, C. S., Mendes, V. G., Abreu-Silva, A. L., Gonçalves da Costa, S. C. & Calabrese, K. S. (2010). Immunopathological studies of Leishmania amazonensis infection in resistant and in susceptible mice. J Infect Dis 201, 1933-1940.
10. Desjeux, P. (2001). The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 95, 239-243.
11. Faria, D. R., Gollob, K. J., Barbosa, J., Jr, Schriefer, A., Machado, P. R. L., Lessa, H., Carvalho, L. P., Romano-Silva, M. A., de Jesus, A.R. & other authors (2005). Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammat ory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun 73, 7853-7859.
12. Fortier, A. H., Leiby, D. A., Narayanan, R. B., Asafoadjei, E., Crawford, R. M., Nacy, C. A. & Meltzer, M. S. (1995). Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth. Infect Immun 63, 1478-1483.
13. Frézard, F., Demicheli, C. & Ribeiro, R. R. (2009). Pentavalent antimonials: new perspectives for old drugs. Molecules 14, 2317-2336.
14. Galvão, L. O., Moreira Júnior, S., Medeiros Júnior, P., Lemos, G. J., Cunha, N. F., Antonino, R. M., Santos Filho, B. S. & Magalhães, A.V. (2000). Therapeutic trial in experimental tegumentary leishmaniasis caused by Leishmania (Leishmania) amazonensis. A comparative study between mefloquine and aminosidine. Rev Soc Bras Med Trop 33, 377-382.
15. Ghedin, E., Debrabant, A., Engel, J. C. & Dwyer, D. M. (2001). Secretory and endocytic pathways converge in a dynamic endosomal system in a primitive protozoan. Traffic 2, 175-188.
16. Gomes, I. N., Calabrich, A. F., Tavares, R. S., Wietzerbin, J., de Freitas, L. A. & Veras, P. S. (2003). Differential properties of CBA/J mononuclear phagocytes recovered from an inflammatory site and probed with two different species of Leishmania. Microbes Infect 5, 251-260.
17. Guimarães, E. T., Santos, L. A., dos Santos, R. R., Teixeira, M. M., dos Santos, W. L. C. & Soares, M. B. P. (2006). Role of interleukin-4 and prostaglandin E2 in Leishmania amazonensis infection of BALB/c mice. Microbes Infect 8, 1219-1226.
18. Heurtault, B., Legrand, P., Mosqueira, V., Devissaguet, J.-P., Barratt, G. & Bories, C. (2001). The antileishmanial properties of surface-modified, primaquine-loaded nanocapsules tested against intrama-crophagic Leishmania donovani amastigotes in vitro. Ann Trop Med Parasitol 95, 529-533.
19. Hrabák, A., Sefrioui, H., Vercruysse, V., Temesi, A., Bajor, T. & Vray, B. (1998). Action of chloroquine on nitric oxide production and parasite killing by macrophages. Eur J Pharmacol 354, 83-90.
20. Huynh, C., Sacks, D. L. & Andrews, N. W. (2006). A Leishmania amazonensis ZIP family iron transporter is essential for parasite replication within macrophage phagolysosomes. J Exp Med 203, 2363-2375.
21. Ingram, K., Ellis, W. & Keiser, J. (2012). Antischistosomal activities of mefloquine-related arylmethanols. Antimicrob Agents Chemother 56, 3207-3215.
22. Jang, C.-H., Choi, J.-H., Byun, M.-S. & Jue, D.-M. (2006). Chloroquine inhibits production of TNF-a, IL-1b and IL-6 from lipopolysacchar-ide-stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford) 45, 703-710.
23. Kaye, P. & Scott, P. (2011). Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 9, 604-615.
24. Keiser, J., Manneck, T. & Vargas, M. (2011). Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro. J Antimicrob Chemother 66, 1791-1797.
25. Khan, I., Yasmin, R. & Sidiki, I. (2007). Chloroquine in cutaneous leishmaniasis. J Pak Assoc Dermatol 17, 95-100.
26. Küster, T., Stadelmann, B., Hermann, C., Scholl, S., Keiser, J. & Hemphill, A. (2011). In vitro and in vivo efficacies of mefloquine-based treatment against alveolar echinococcosis. Antimicrob Agents Chemother 55, 713-721.
27. Laguna-Torres, V. A., Silva, C. A., Correia, D., Carvalho, E. M., Magalhães, A. V. & Macêdo, Vde. O. (1999). [Mefloquine in the treatment of cutaneous leishmaniasis in an endemic area of Leishmania (Viannia) braziliensis.]. Rev Soc Bras Med Trop 32, 529-532 (in Portuguese).
28. Landires, E. A. G., Andrial, M., Hosokawa, A., Nonaka, S. & Hashiguchi, Y. (1995). Oral treatment of new world cutaneous leishmaniasis with anti-malarial drugs in Ecuador: a preliminary clinical trial. Jpn J Trop Med Hyg 23, 151-157.
29. Lemos de Souza, V., Ascenção Souza, J., Correia Silva, T. M., Sampaio Tavares Veras, P. & Rodrigues de-Freitas, L. A. (2000). Different Leishmania species determine distinct profiles of immune and histopathological responses in CBA mice. Microbes Infect 2, 1807-1815.
30. Murray, H. W., Berman, J. D., Davies, C. R. & Saravia, N. G. (2005). Advances in leishmaniasis. Lancet 366, 1561-1577.
31. Noor, S. M., Khan, M. M. & Hussain, D.(2005). Intralesional chloroquine in cutaneous leishmaniasis. J Pak Assoc Dermatol 15, 18-21.
32. O'Neill, P. M., Bray, P. G., Hawley, S. R., Ward, S. A. & Park, B. K. (1998). 4-Aminoquinolines-past, present, and future: a chemical perspective. Pharmacol Ther 77, 29-58.
33. Oliveira, L. F., Schubach, A. O., Martins, M. M., Passos, S. L., Oliveira, R. V., Marzochi, M. C. & Andrade, C. A. (2011). Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop 118, 87-96.
34. Pereira, B. A. S. & Alves, C. R. (2008). Immunological characteristics of experimental murine infection with Leishmania (Leishmania) amazonensis. Vet Parasitol 158, 239-255.
35. Reithinger, R., Dujardin, J. C., Louzir, H., Pirmez, C., Alexander, B. & Brooker, S. (2007). Cutaneous leishmaniasis. Lancet Infect Dis 7, 581-596.
36. Rolain, J. M., Colson, P. & Raoult, D. (2007). Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 30, 297-308.
37. Sen, R., Ganguly, S., Saha, P. & Chatterjee, M. (2010). Efficacy of artemisinin in experimental visceral leishmaniasis. Int J Antimicrob Agents 36, 43-49.
38. Smith, D. F., Peacock, C. S. & Cruz, A. K. (2007). Comparative genomics: from genotype to disease phenotype in the leishmaniases. Int J Parasitol 37, 1173-1186.
39. Taylor, M. C. & Kelly, J. M. (2010). Iron metabolism in trypanoso-matids, and its crucial role in infection. Parasitology 137, 899-917.
40. WHO (2010). Control of Leishmaniasis: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniasis, Geneva, 22-26 March 2010. WHO Technical Report Series no. 949. Geneva: World Health Organization.
41. Yang, D. M. & Liew, F. Y. (1993). Effects of qinghaosu (artemisinin) and its derivatives on experimental cutaneous leishmaniasis. Parasitology 106, 7-11.